Tag Archives: T-regulatory cell engineering

Innovative Partnership: AstraZeneca and Quell Therapeutics Targeting Autoimmune Diseases with Engineered Treg Cell Therapies

Posted on 9, June 2023 by EuropaWire PR Editors

(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release →

Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom

Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes